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Fig. S1. TILs in untreated mice. Fig. S2 . Adoptive transfer of TCR Vβ6, 7, 8.1/8.2, or 11 does not provide survival benefit against NSC. Fig. S3 . Relative expansion of TCR Vβ families in peripheral blood after ACT. Fig. S4 . Tumor-reactive T cells retain function within tumor. Fig. S5 . ACT in recurrent medulloblastoma and PNET. Fig. S6 . Lack of single clonal expansion over time in nonresponder to ACT. Table S1 . Clonal expansion in patient PBMCs after ACT. Table S2 . Productive frequency of TCR Vβ families in patient MNCs before ACT, ex vivo expanded ttRNA T cells, and at follow-up after T cell infusion. Fig. S1 . TILs in untreated mice. A) C57BL/6 mice received orthotopic NSC medulloblastoma and left untreated until symptomatic of disease. Tumors were harvested and processed into single cell suspension for flow cytometry. The relative frequency of fifteen TCR Vβ families was determined from the tumor tissue (n=5 mice. This was repeated three additional times). B) C57BL/6 mice received orthotopic KR158B high-grade glioma and left untreated until symptoms of disease were observed. The relative frequency of fifteen TCR Vβ families was determined by flow cytometry from the tumor tissue (n=5 mice). S4 . Tumor-reactive T cells retain function within tumor. C57BL/6 mice received orthotopic NSC medulloblastoma or KR158B high-grade glioma then treated with adoptive cellular therapy using tumor-reactive T cells generated using DsRed+ mice. Responders to therapy had no detectable tumor by bioluminescent imaging. In non-responders to ACT, tumors were harvested at endpoint and the tumor infiltrating lymphocytes from DsRed+ T cells was spectratyped for TCR Vβ family expansion. A) In NSC tumor-bearing mice that did not respond to ACT, we found no hyper-expansion of any TCR V β families derived from the adoptively transferred cells. B) In KR158B tumor-bearing mice, we found relative expansion of TCR Vβ 7 + and 8.1/8.2 + DsRed+ T lymphocytes. C) TCR Vβ 7 + and 8.1/8.2 + DsRed + T lymphocytes were then FACS isolated from the tumor. Each cell type was then used as effectors in an in vitro functionality assay to determine if they maintained anti-reactivity. IFNγ secretion was measured as an indication of function. Splenic T cells from a completely naïve C57BL/6 mouse were used as a negative control. These experiments were repeated twice with n=5 tumors. Study schema of adoptive cell therapy using autologous ex vivo activated and expanded T cells in children with recurrent medulloblastoma and PNETs. An 11 year old child with recurrent medulloblastoma received surgery followed by high dose chemotherapy and peripheral blood stem cell transplant (2x10 6 CD34+ cells/kg). This was followed by adoptive transfer of autologous tumor-reactive T cells and three autologous tumor RNA-pulsed dendritic cell vaccines. Peripheral blood was drawn at 2, 4, 6, and 16 weeks post-adoptive cellular therapy.
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T o t a l= 9 7 .4 9 6 7 S6 . Lack of single clonal expansion over time in nonresponder to ACT. A patient with recurrent medulloblastoma was treated with adoptive cell therapy (ACT) using autologous ex vivo activated T cells and experienced no response to therapy with <70 days to progression. TCR sequencing was conducted on the patient's tumor-reactive T cells, and on patient peripheral blood mononuclear cells (PBMC) taken at pre-ACT, then at 14, 28, 42, and 54 days post-adoptive cellular therapy. Clonal analysis revealed hyperexpansion of different TCR clones at each time point and that no hyper-expansion of a single clone over time was observed in this non-responder to ACT.
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Table S1. Clonal expansion in patient PBMCs after ACT. Table S2 . Productive frequency of TCR Vβ families in patient MNCs before ACT, ex vivo expanded ttRNA T cells, and at follow-up after T cell infusion.
